Skip to content

Vasopressin in Intraabdominal Pressure Elevation

Correlation Between Vasopressin and Renal Function Following a Controlled Intraabdominal Pressure Elevation

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03707054
Enrollment
16
Registered
2018-10-16
Start date
2017-04-28
Completion date
2024-12-31
Last updated
2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Compartment Syndrome, Intracranial Pressure Increase

Brief summary

The aim of this study is to investigate any direct correlation between increased intrathoracic pressure, intraabdominal pressure and intracranial pressure, following a controlled elevation in intraabdominal pressure and intrathoracic pressure (PEEP). The second end-point is to investigate any correlation between elevated intracranial pressure and vasopressin release, urine output and urine and serum osmolality by measuring their values at different time-points.

Detailed description

Increase in intraabdominal pressure (IAP) has been demonstrated to correlate with consequential hemodynamic effects. Several studies have been carried out mostly in experimental settings to define the underlying mechanisms that regulate the pathophysiology following an increase in IAP. In the last years this topic has become concerning because of the wide spread of laparoscopy, that is namely an iatrogenic acute increase in IAP. Patients selected and consented for elective surgery will undergo standard of care and additional measurements during and after surgery. The measurements will be done at different stages of laparoscopic surgery. 1. A) Baseline, patient under general anesthesia, Foley catheter positioned, beginning urine collection, before insufflation of pneumoperitoneum 2. B) 10-15 minutes after insufflation of pneumoperitoneum at 15mmHg, PEEP at 5cmH2O or lowest setting 3. C) 10-15 minutes after stabilization of PEEP at 10cmH2O, pneumoperitoneum still at 15 mmHg 4. D) 10-15 minutes after desufflation of pneumoperitoneum and basal mechanical ventilation Measurements include : * Intraabdominal pressure IAP: assessed via laparoscopic insufflator, set at 15 mmHg as a standard value for all laparoscopic procedures * Intrathoracic pressure: indirectly measured by variability of peak expiratory pressures * Urine collection: through a Foley catheter from the beginning of surgery to post-operative day 1 * Urine osmolality (to be assessed at set time-points ) * Hourly urine output (at least 24 hours in order to evaluate expected significant variation even after the procedure end, since renal adaptation could take longer period) * Serum/plasma collection : blood draws to evaluate specific values of * Plasma Vasopressin (ADH) * Serum osmolality * Mean arterial pressure : standard of care * Pulmonary expiratory end-pressure (PEEP): anesthesiologists routinely adapt PEEP in order to maintain an optimal ventilation, especially in obese patients and during laparoscopy * Optic nerve sheath diameter (ONSD): a 7.5-MHz linear ultrasound probe to measure the diameter of the optic nerve sheath 3 mm behind the globe is going to be used; a trained study personnel physician will take the non-invasive sonographic picture using ultrasound. The ONSD will be measured from the captured picture. Study personnel will record the interaction on the patient's chart and include the measurement on the database

Interventions

DIAGNOSTIC_TESTStudy Arm

Measurements of optic nerve diameter, serum and urine osmolarity, serum vasopressin

Sponsors

The Cleveland Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

prospective trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 72 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-72 * Patients meeting NIH criteria for bariatric surgery * Patients undergoing laparoscopic sleeve gastrectomy

Exclusion criteria

* • Age below 18 years * American Society of Anesthesiologist (ASA) class IV or V * Other evident/diagnosed causes of increased IAP or increased intrathoracic pressure, except for obesity * Active urinary tract infection * Previous or concomitant neurological disease * Previous or concomitant ophthalmic conditions/eye surgery * Previous or concomitant lung diseases

Design outcomes

Primary

MeasureTime frameDescription
Changes in Vasopressin Levels During Pneumoperitoneum and Elevated PEEPIntraoperative - approximately 45-60 minutes (Baseline, 10-15 minutes after pneumoperitoneum, 10-15 minutes after PEEP increase, and 10-15 minutes after desufflation)The investigators will measure the intrabdominal pressure (IAP) pressure using the laparoscopic insufflator dial, the optic nerve sheath diameter (OSND) using an ultrasound which is a surrogate of the intracranial pressure (ICP), the variation of vasopressin levels, and the urine osmolality at baseline and during pneumoperitoneum. This is done in an effort to understand the compensatory measure used during pneumoperitoneum and abdominal compartment syndrome

Countries

United States

Participant flow

Recruitment details

Sixteen adult patients undergoing elective laparoscopic sleeve gastrectomy for severe obesity were prospectively enrolled between 2017 and 2019 at Cleveland Clinic Florida. All participants provided written informed consent.

Pre-assignment details

No randomization or allocation was performed. All enrolled patients underwent the same surgical procedure and intraoperative physiologic measurements at four predefined time points (baseline, pneumoperitoneum, elevated PEEP, and end). No patients were excluded after enrollment.

Baseline characteristics

Characteristic
Age, Continuous45.0 years
STANDARD_DEVIATION 10
Body Mass Index (BMI)41.1 kg/m²
STANDARD_DEVIATION 4.4
Region of Enrollment
United States
16 participants
Sex: Female, Male
Female
11 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 16
other
Total, other adverse events
0 / 16
serious
Total, serious adverse events
0 / 16

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 30, 2026